http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20030090918-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_319ac9d729dcf44fc0463b2d37d25e6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa0a8a718cac5315e779c640ffd410b4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10032
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01
filingDate 2002-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13731a8ccab009be72d04032062b30d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bced27a1d93849ea247d70643d08df63
publicationDate 2003-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20030090918-A
titleOfInvention Recombinant Adenovirus with Enhanced Tumoricidal Effect and Pharmaceutical Composition Comprising the Same
abstract The present invention relates to recombinant adenoviruses having an improved tumor killing effect. The present invention provides a recombinant adenovirus and a pharmaceutical antitumor composition comprising the same by introducing an infective ligand of a vesicular stomatitis virus into an adenovirus to enhance antitumor activity. The recombinant adenovirus of the present invention enables high efficiency gene delivery with the administration of a smaller amount of virus, thereby overcoming disadvantages such as inducing the immune response of the host and inducing toxicity, which are the biggest limitations of the gene delivery system using adenovirus. Therefore, it may be widely used in tumor cells with low gene transduction rate and cells with severe toxicity and side effects caused by administration of high titer of adenovirus.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017155281-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10849987-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019066535-A1
priorityDate 2002-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID105035
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4915
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID10535
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419508556
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537453
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID791793
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID11276
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID10535
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID750
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493463
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP09638
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID11276
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14075609
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281733
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419521105
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID89843
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419521378
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6550
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6323481
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13052
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419545322
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452041513

Total number of triples: 42.